PROGRAMME

11:00–11:30Registration
11:30–11:40 Welcome and introduction
Everett Vokes (USA)
11:40–12:05 What is the current clinical status of novel immunotherapies in advanced NSCLC?
Luis Paz-Ares (Spain)
12:05–12:30 What does the latest evidence reveal for emerging MET inhibitors?
Ross Camidge (USA)
12:30–12:55 Are we optimally prepared to provide personalized treatment strategies?
Martin Reck (Germany)
12:55–13:00 Summary and adjournment
Everett Vokes (USA)

EDUCATIONAL PARTNER
Ology Medical Education
info@ologyeducation.org